Carregant...
Is there clinical value to prognostic signatures in early stage NSCLC?
pAMPK and pmTOR favorably predicted outcome in early NSCLC. The differences were small. Phosphoprotein lability makes routine clinical use and validation difficult. Protein IHC is unlikely to be clinically useful and numerous efforts to create predictive models to select resected patients for therap...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3998101/ https://ncbi.nlm.nih.gov/pubmed/24583801 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-3387 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|